AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
26 mars 2022 00h12 HE
|
AnPac Bio-Medical Science Co., Ltd.
PHILADELPHIA, March 26, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and...
AnPac Bio-Medical Sciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
11 mars 2022 16h30 HE
|
AnPac Bio-Medical Science Co., Ltd.
PHILADELPHIA, March 11, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and...
AnPac Bio’s Bio-Chip Subsidiary, Changwei System Technology Co., Ltd., Receives Independent Valuation and Approval from the Board to Explore Strategic Alternatives
03 mars 2022 07h00 HE
|
AnPac Bio-Medical Science Co., Ltd.
PHILADELPHIA, March 03, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and...
AnPac Bio Files CDA Device for Breakthrough Medical Device Designation Request with the FDA
03 févr. 2022 07h30 HE
|
AnPac Bio-Medical Science Co., Ltd.
PHILADELPHIA, Feb. 03, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and...
Leading US Market Analysis and Research Firm Ranked AnPac Bio Globally Number One in Multi-Cancer Screening and Detection Test Volume
25 janv. 2022 07h30 HE
|
AnPac Bio-Medical Science Co., Ltd.
PHILADELPHIA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and...
AnPac Bio Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
24 janv. 2022 17h00 HE
|
AnPac Bio-Medical Science Co., Ltd.
PHILADELPHIA, Jan. 24, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States...
AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests and Will Start Clinical Trial in Q1, 2022
04 janv. 2022 07h30 HE
|
AnPac Bio-Medical Science Co., Ltd.
PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a US and China-based biotechnology company focused on early cancer...
Technical Paper on AnPac Bio Novel CDA Cancer Detection Technology Published by Peer-Reviewed International Medical Journal
10 déc. 2021 07h30 HE
|
AnPac Bio-Medical Science Co., Ltd.
PHILADELPHIA, Dec. 10, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the...
AnPac Bio Reports Nine Months Ended September 30, 2021, Same Period Achieved Record Revenue Increased By 55.3% While Non-GAAP Net Loss Reduced by 6.8%
26 nov. 2021 13h30 HE
|
AnPac Bio-Medical Science Co., Ltd.
PHILADELPHIA, Nov. 26, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the...
CORRECTION -- Anpac Bio, USA
11 nov. 2021 03h19 HE
|
Anpac Bio, USA
PHILADELPHIA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- In its press release dated November 9, 2021 entitled “AnPac Bio Announces Pricing of Approximately $2.9 Million Underwritten Public Offering of...